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Abstract
Fanconi anemia is a rare disease, which is characterized by decreased production of all blood cell types.
Fanconi anemia is the most common inherited form of aplastic anemia. Congenital abnormalities of the eyes,
ears, and heart, malformed or absent kidney, urogenital system involvement are common. There is a delay
in physical development. Intelligence in patients with Fanconi anemia is usually normal. The most serious
problems associated with Fanconi anemia include the gradual development of bone marrow disorders. Many
patients with Fanconi anemia develop leukemia or myelodysplastic syndrome, as well as other oncological
diseases. Oral manifestations in patients with Fanconi anemia can be classified as gingivitis, periodontitis, dental
caries, dental anomalies, soft tissue lesions, oral cancer, and lesions of the tongue. Patients with Fanconi
anemia have increased predisposition to squamous cell carcinoma of the head and neck and oral cancer.
The interdisciplinary team of medical and dental specialists must be included in the medical and dental treatment
of patients with Fanconi anemia. For proper dental care of patients with Fanconi anemia, the close cooperation
of dental specialists, including orthodontists, pedodontists, prosthetists, oral surgeons, as well as specialists in
periodontology and oral diseases, is of particular importance.
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Introduction
Fanconi anemia (FA) is a rare disease, which bears the name
of the famous Swiss paediatrician Guido Fanconi, who first
discovered the disease [1]. The average birth rate of children
with FA is approximately 1 case per 350, 000 newborns. It
occurs with the same frequency in both males and females,
among all nationalities [1]. FA is a congenital disorder that is
inherited in an autosomal recessive manner, i.e., if the father
and mother are carriers of the defective gene (they can be
completely clinically healthy), then, with each delivery, there
is a 25% risk for a child to have this disease. There is a lack of
literature dealing with the most prevalent oral manifestations
seen in patients with FA. The incidence of FA is increasing in
communities of people where marriages are closely related.
At least 22 faulty genes are associated with FA [2]; however,
new deletions of already known genes are still being discov-
ered [3]. Since the treatment of this rare disease requires
a multidisciplinary approach, dentists’ knowledge about early
diagnosis and appropriate treatment of oral manifestations, as
well as prevention of squamous cell carcinoma is of particular
importance.
The objective of this review was to focus on the literature
dealing with oral changes and their relationship to the overall
health and well-being of patients with FA from the dentist’s
point of view.
Signs and Symptoms
Congenital aplastic anemia is usually diagnosed at 4 to 12
years of age through pancytopenia. It can occur as isolated
anemia, or anemia with co-existent leukopenia or thrombo-
cytopenia. Children with FA often develop characteristic
physical anomalies: skeletal malformations (e.g., thumbs,
wrist bones, thighs, spine, ribs), short stature, bird-headed
facial appearance, skin changes - hypopigmentation, light-to-
dark-brown coffee-colored skin. Congenital abnormalities of
the eyes, ears, and heart, malformed or absent kidney, urogen-
ital system involvement are common [4, 5]. There is a delay
in physical development. Intelligence in patients with FA is
usually normal. More than 50% of patients have physical
abnormalities. These also may include brain malformations
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(small head size, excess fluid in the brain), genital abnormali-
ties [5].
The most serious problems associated with FA include
the gradual development of bone marrow disorders. They
usually become noticeable at the age of 5-10 years and, then,
worsen over time, although sometimes the disease is almost
asymptomatic for many years. Decreased platelet count leads
to increased bleeding (easy bruising and nasal bleeding); de-
creased red blood cell count leads to weakness and fatigue;
decreased leukocyte count (neutrophils) leads to poor re-
sistance to infections. Many patients develop leukemia or
myelodysplastic syndrome [6], as well as other oncological
diseases [2, 7].
Oral Manifestations of FA
Thrombocytopenia seen in patients with FA promoted inflam-
mation of the gums, especially considering the fact that these
patients have undergone long-term hospital treatment since
early childhood, where there were no adequate conditions for
maintaining oral hygiene [8]. According to Gaitán-Fonseca C,
there is no epidemiological data on the incidence of FA in
Mexico and many cases remain undiagnosed. After applica-
tion of the obturator over the palatal cleft, a significant reduc-
tion in the ear, tonsil and throat infections was noticed [9].
In patients with FA, especially after hematopoietic stem
cell transplantation (HSCT), there is an increased risk of ma-
lignant diseases of the oral cavity. A wide range of oral
manifestations occurring in patients with FA is shown in Ta-
ble 1. Calcineurin inhibitors are medications commonly used
for long periods of time in patients undergoing allogeneic
HSCT. Cases of children with FA, who developed similar oral
mucosal lesions associated with the use of cyclosporine, phe-
nobarbital, and amlodipine after HSCT, have been described
in the literature [10]. Patients with FA have increased predis-
position to squamous cell carcinoma of the anogenital tract
and head and neck region [11]. In addition, many studies have
linked FA to oral cancer [7, 12, 13] and some have assessed
the risk of developing oral cancer [14, 15].
Lyko K et al. from Brazil conducted a comparative study
including 35 patients with FA and 35 healthy individuals
(the control group) to investigate the difference between their
dental caries experience, dental care level, and oral hygiene.
In their study, FA patients demonstrated higher values of
the decay-missing-filled index (DMFI), the dental care index,
the oral hygiene index; however, there was no statistically
Table 1. Clinical studies on oral and dental manifestations of Fanconi anemia.
No. Authors Patients Key Oral Findings Reference
1. Touil D et al. Ten-year-old boy Microdontia and advanced periodontitis
[8] Case Reports in
Dentistry.
2020;2020:3161053.
2. Gaitán-Fonseca C et al. Newborn Cleft palate [9] Odovtos-Int J DentSc. 2018;20(3):25-31.





4. Kaul R et al. Three-year-oldfemale child Spontaneous gingival bleeding at night
[17] SRM J Res Dent
Sci. 2017;8(2):92-96.
5. Miranda F et al. Eight-year-oldfemale patient
Class III skeletal pattern and maxillary
lateral incisor agenesis
[18] Special Care in
Dentistry.
2020;40(4):382–389.
6. Goswami M et al. Five-year-oldmale patient
Mesiodens, retained deciduous mandibu-
lar incisors and delayed eruption of
permanent mandibular incisors, white
patches on the dorsal surface of the
tongue, traumatic bite lesions with de-




7. Perdoncini NN et al.
Fifty-six patients
with FA over 11
years of age
The average DMFI = 5.23, the Visible
Plaque Index = 31.36% and the Gingival




8. de Araujo MR et al. Thirty-threepatients
Melanin pigmentation in the oral mucosa,
traumatic lesions, agenesis, taurodontism,
radicular anomalies such as dilaceration,
tapering, and foreshortening, gingival
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significant difference between the groups [16]. Several case
reports of FA patients of different ages have been described in
the literature [17]. The individual approach to dental treatment
depended on the oral health status and the need for orthodontic
treatment [18].
In a case report of a 5-year-old male from India, Goswami
M et al. described the presence of mesiodens in the lower
jaw, which is very rare. Delayed tooth eruption, as well as
other dental anomalies were also present. Hyposalivation
was common in FA patients due to endocrine dysfunction,
which further increased the susceptibility to dental caries in
these patients [19]. Recurrent aphthous ulcers are thought
to develop in FA patients due to neutropenia and anemia, as
soft tissue ulcers heal within the weeks after blood transfu-
sion [19]. Perdoncini NN et al. in Brazil compared the an-
swers to the questionnaire regarding the periodontal health
and clinical measurements of the periodontal status among
individuals with FA and concluded that they were able to
perceive gingivitis manifested by gingival bleeding [20].
Melanin pigmentation of the oral mucosa, traumatic le-
sions, gingival bleeding, dental biofilm, and gingival alter-
ations were the main oral manifestations found in the study
conducted by de Araujo MR et al. in Brazil [21].
Tekcicek M et al. investigated 26 FA children from
the central region of Anatolia and find poor oral hygiene
and 30%-prevalence of dental caries, while radiological ex-
amination revealed microdontia, congenitally missing teeth,
transposition, and supernumerary teeth in 44%, 26%, 9% and
4% of children, respectively [22]. Açikgöz A et al. inves-
tigated the oral health, including oral lesions, gingival and
periodontal status in 15 children with FA from Ankara. They
stated that the increased tendency toward periodontal disease
might be due to anemia, leukopenia, and defective detoxifica-
tion of oxygen radicals that are characteristic of FA itself, as
well as to medications used during intense immunosuppres-
sive treatment, such as steroids [23].
Diagnostics
FA may be suspected in a child with some of the signs listed
above, combined with changes in clinical blood parameters.
Other signs worth mentioning are hyperreflexia, hypogonadism,
microcephaly, microphthalmia, strabismus, ptosis, nystag-
mus, and ear abnormalities. Macrocytosis, high mean cell
volume, increased fetal hemoglobin, excess erythropoietin
can be seen in the blood count of FA patients. There may
be a deficiency of all blood cells, as well as a decrease in
the number of platelets or leukocytes. The Diepoxybutane
Test is used to make a diagnosis. The diagnosis can be made
by means of a karyogram and karyotype to detect chromo-
somal abnormalities. The cellular composition of the bone
marrow (myelogram) is examined for diagnosis clarification.
The bone marrow biopsy reveals whether it is hypocellular or
fatty [1]. In families where there have been cases of childbirth
with FA, for all subsequent pregnancies, it is recommended
a prenatal diagnosis to be done using cordocentesis (taking
umbilical cord material) to find out the risk that the fetus has
FA [24]. Furthermore, examination for FA is recommended
when a child is born with skeletal abnormalities, especially
arm abnormalities.
Treatment
Supportive therapy which involves transfusion of filtered ery-
throcytes and platelets (irradiated depleted leukocytes) is
mainly used for treating FA. Chelation therapy due to iron
overload, androgen hormones, as well as allogeneic heart
transplantation are applied as well.
In November 2018, the first unrelated donor-hematopoietic
stem cell transplantation in the Republic of North Macedo-
nia was performed at the University Clinic of Hematology.
It is one of the most modern and complex biological inter-
ventions that allows the most severe hematological diseases
to be treated without surgery [25]. This opened the possi-
bility to treat patients with FA in our country. Macedonian
public health has entered the map of world and European
medical centers for treating the most serious blood diseases.
The Macedonian Bone Marrow Donor Registry, established
within the Institute of Immunobiology and Human Genet-
ics, Medical Faculty, Skopje, Macedonia, is a member of
the World Marrow Donor Association.
Allogeneic bone marrow transplantation is the only chance
to achieve normalization of blood formation in patients with
FA [26]. In this case, it is highly desirable to perform the trans-
plant while a patient is still young, optimally up to 10 years
of age. If a patient has healthy siblings who are compatible
as potential donors, then, transplantation is recommended.
Patients with FA are particularly sensitive to chemotherapy
(as well as radiotherapy); therefore, special conditioning pro-
tocols should be used [27]. FA patients with advanced oral
cancer require a combination of surgery, radiotherapy, and
chemotherapy for appropriate treatment. To reduce the ad-
verse effects of radiation in FA patients with oral cancer or
head and neck cancer, experimental tests are performed on FA
mice irradiated with proton therapy to reduce the occurrence
of inflammation of the oral mucosa [28]. Infection control is
the most important part of dental treatment for FA patients.
Radiographic examination is not recommended as X-rays
may induce tumor development. If a patient is not prepared
in advance, even a routine tooth extraction can cause a crisis.
Non-invasive dental interventions do not require transfusion
of platelets. Desmopressin and antifibrinolytic drugs are used
in more invasive and shorter dental procedures, while platelet
transfusions are used in more severe, long-lasting dental inter-
ventions.
Treatment Prognosis
The life expectancy of patients with FA depends on how
severely the bone marrow function is impaired. Some patients
live 30-40 years without treatment; however, many people
die in childhood, either from the disease itself or from cancer
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that has resulted from the disease. Therefore, it is so impor-
tant to have an allogeneic bone marrow transplant over time -
this is the only chance to restore normal blood formation and
increase life expectancy.
Pediatric transplants from healthy compatible donor rela-
tives (siblings) lead to success in most FA patients, although
such transplants should be screened regularly for early detec-
tion of possible malignancies in various organs - the likeli-
hood of their occurrence remains high, even after transplanta-
tion [29].
Conclusions
The interdisciplinary team of medical and dental special-
ists must be included in the medical and dental treatment
of patients with FA. Medical doctors, especially hematolo-
gists, nephrologists, dermatovenerologists, ophthalmologists,
otorhinolaryngologists, and dentists play an important role
in treating FA. They have to work together in order to im-
prove oral health-related quality of life of patients with FA.
FA patients really need special dental care.
Ethical Statement
This article does not include any human participants and/or
animals.
Conflict of Interest
The author declares that no conflicts exist.
Financial Disclosure
The author declared no financial support.
References
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Duru F, Yarali N, et al. Oral and dental find-
ings in Fanconi’s anemia. Pediatric Hematology
and Oncology. 2005;22(6):531–539. Available from:
https://doi.org/10.1080/08880010591002413
[24] Lee HJ, Park S, Kang HJ, Jun JK, Lee JA, Lee DS, et al.
A case report of Fanconi anemia diagnosed by genetic
testing followed by prenatal diagnosis. Annals of Lab-
oratory Medicine. 2012;32(5):380–384. Available from:
https://doi.org/10.3343/alm.2012.32.5.380
[25] Panovska-Stavridis I, Pivkova-Veljanovska A, Ridova
N, Stojanovski Z, Cadievski L, Trajkova S, et al.
Molecular monitoring in acute myeloid leukemia pa-
tients undergoing matched unrelated donor – hematopoi-
etic stem cell transplantation: single center expe-
rience. PRILOZI. 2020;41(3):5–12. Available from:
https://doi.org/10.2478/prilozi-2020-0040
[26] Ebens CL, MacMillan ML, Wagner JE. Hematopoi-
etic cell transplantation in Fanconi anemia: current ev-
idence, challenges and recommendations. Expert Re-
view of Hematology. 2016;10(1):81–97. Available from:
https://doi.org/10.1080/17474086.2016.1268048
[27] Mehta PA, Davies SM, Leemhuis T, Myers K,
Kernan NA, Prockop SE, et al. Radiation-free,
alternative-donor HCT for Fanconi anemia patients:
results from a prospective multi-institutional study.
Blood. 2017;129(16):2308–2315. Available from:
https://doi.org/10.1182/blood-2016-09-743112
[28] Quinn TJ, Ding X, Li X, Wilson GD, Buelow K,
Sivananthan A, et al. Amelioration of mucositis in pro-
ton therapy of Fanconi anemia Fanca–/– mice by JP4-
039. In Vivo. 2019;33(6):1757–1766. Available from:
https://doi.org/10.21873/invivo.11666
[29] Abram TJ, Pickering CR, Lang AK, Bass NE, Raja R,
Meena C, et al. Risk stratification of oral potentially ma-
lignant disorders in fanconi anemia patients using autoflu-
orescence imaging and cytology-on-a chip assay. Trans-
lational Oncology. 2018;11(2):477–486. Available from:
https://doi.org/10.1016/j.tranon.2018.01.014
Received: 2021-03-26
Revised: 2021-04-28
Accepted: 2021-05-12
